Index of artpub/2022/275796/

Cree, Bruce A. C
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis : Up to 5 years of follow-up in the DAYBREAK open-label extension trial
2022
https://ddd.uab.cat/record/275796